Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 209

1.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG.

J Clin Oncol. 2007 May 1;25(13):1658-64.

PMID:
17470858
[PubMed - indexed for MEDLINE]
Free Article
2.

FDA drug approval summary: panitumumab (Vectibix).

Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R.

Oncologist. 2007 May;12(5):577-83.

PMID:
17522246
[PubMed - indexed for MEDLINE]
Free Article
3.

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.

Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer W, Spadafora S, Amado RG, Hogan N, Peeters M.

Ann Oncol. 2008 Jan;19(1):92-8. Epub 2007 Sep 4.

PMID:
17785764
[PubMed - indexed for MEDLINE]
Free Article
4.

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J.

J Clin Oncol. 2010 Nov 1;28(31):4706-13. doi: 10.1200/JCO.2009.27.6055. Epub 2010 Oct 4.

PMID:
20921462
[PubMed - indexed for MEDLINE]
Free Article
5.

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.

Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ.

Cancer. 2007 Sep 1;110(5):980-8.

PMID:
17671985
[PubMed - indexed for MEDLINE]
Free Article
6.

Panitumumab: in the treatment of metastatic colorectal cancer.

Hoy SM, Wagstaff AJ.

Drugs. 2006;66(15):2005-14; discussion 2015-6. Review.

PMID:
17100412
[PubMed - indexed for MEDLINE]
7.

Panitumumab: a review of its use in metastatic colorectal cancer.

Keating GM.

Drugs. 2010 May 28;70(8):1059-78. doi: 10.2165/11205090-000000000-00000. Review.

PMID:
20481659
[PubMed - indexed for MEDLINE]
8.

Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer.

Wu M, Rivkin A, Pham T.

Clin Ther. 2008 Jan;30(1):14-30. doi: 10.1016/j.clinthera.2008.01.014. Review.

PMID:
18343240
[PubMed - indexed for MEDLINE]
9.

A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer.

Muro K, Yoshino T, Doi T, Shirao K, Takiuchi H, Hamamoto Y, Watanabe H, Yang BB, Asahi D.

Jpn J Clin Oncol. 2009 May;39(5):321-6. doi: 10.1093/jjco/hyp016. Epub 2009 Mar 14.

PMID:
19287023
[PubMed - indexed for MEDLINE]
Free Article
10.

U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

Giusti RM, Shastri K, Pilaro AM, Fuchs C, Cordoba-Rodriguez R, Koti K, Rothmann M, Men AY, Zhao H, Hughes M, Keegan P, Weiss KD, Pazdur R.

Clin Cancer Res. 2008 Mar 1;14(5):1296-302. doi: 10.1158/1078-0432.CCR-07-1354.

PMID:
18316547
[PubMed - indexed for MEDLINE]
Free Article
11.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD.

J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116. Epub 2008 Mar 3.

PMID:
18316791
[PubMed - indexed for MEDLINE]
Free Article
12.

Panitumumab: in metastatic colorectal cancer with wild-type KRAS.

Weber J, McCormack PL.

BioDrugs. 2008;22(6):403-11. doi: 10.2165/0063030-200822060-00006. Review.

PMID:
18998757
[PubMed - indexed for MEDLINE]
13.

Spotlight on panitumumab in metastatic colorectal cancer.

Keating GM.

BioDrugs. 2010 Aug 1;24(4):275-8. doi: 10.2165/11205460-000000000-00000. Review.

PMID:
20623992
[PubMed - indexed for MEDLINE]
14.

Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer.

Hecht JR, Mitchell E, Neubauer MA, Burris HA 3rd, Swanson P, Lopez T, Buchanan G, Reiner M, Gansert J, Berlin J.

Clin Cancer Res. 2010 Apr 1;16(7):2205-13. doi: 10.1158/1078-0432.CCR-09-2017. Epub 2010 Mar 23. Erratum in: Clin Cancer Res.2010 May 15;16(10):2917.

PMID:
20332321
[PubMed - indexed for MEDLINE]
Free Article
15.

Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.

Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S, Colucci G, Cortesi E, Nichelatti M, Gambacorta M, Siena S.

J Clin Oncol. 2007 Aug 1;25(22):3238-45.

PMID:
17664472
[PubMed - indexed for MEDLINE]
Free Article
16.

Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.

Peeters M, Siena S, Van Cutsem E, Sobrero A, Hendlisz A, Cascinu S, Kalofonos H, Devercelli G, Wolf M, Amado RG.

Cancer. 2009 Apr 1;115(7):1544-54. doi: 10.1002/cncr.24088.

PMID:
19189371
[PubMed - indexed for MEDLINE]
Free Article
17.

Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer.

Saadeh CE, Lee HS.

Ann Pharmacother. 2007 Apr;41(4):606-13. Epub 2007 Mar 13. Review.

PMID:
17355997
[PubMed - indexed for MEDLINE]
18.

[Panitumumab].

Musch A.

Med Monatsschr Pharm. 2008 Apr;31(4):122-6. Review. German.

PMID:
18497243
[PubMed - indexed for MEDLINE]
19.

Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.

Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C.

J Clin Oncol. 2008 Apr 1;26(10):1698-704. doi: 10.1200/JCO.2006.09.9887.

PMID:
18375898
[PubMed - indexed for MEDLINE]
Free Article
20.

A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.

Wang J, Zhao Z, Barber B, Sherrill B, Peeters M, Wiezorek J.

Br J Cancer. 2011 Jun 7;104(12):1848-53. doi: 10.1038/bjc.2011.179. Epub 2011 May 24.

PMID:
21610704
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk